Unit-dose and bi-dose nasal sprays are disposable and generally have a smaller profile than multi-dose nasal sprays, which can make them easier to carry and may translate to improved patient compliance. Unit-dose and bi-dose devices can also provide highly precise drug-delivery volumes, reduce risks from microbial contamination and be made tamper-evident. They can be used to treat many central nervous system conditions, including Parkinson's disease, opioid abuse, epilepsy/seizures and pain applications such as acute/breakthrough pain, cancer-related pain, chronic pain and migraine. Catalent Inhalation offers comprehensive, end-to-end services to help expedite your nasal spray product from concept to market.

Catalent Inhalation
+ 1 888 SOLUTION (765-8846)
catalent.com/inhalation

 

 

This article discusses "repurposing" of oral or parenteral products to the inhaled form, which can be a promising way to develop products for treatment of many serious diseases, particularly where the lung is the natural site of action or optimal delivery location. A key question is, "Why are we repurposing the drug for inhalation?" The answer will guide foundational activities such as drug and target selection; preclinical activities; clinical studies; chemistry, manufacturing and controls (CMC)/quality and commercial positioning of the product. In addition, a number of important factors, such as target product profile, product quality, pharmacology and clinical strategy, should be taken into account early in the drug development process. Considering these factors may increase chances that a repurposed product could be positioned for successful clinical studies and commercial adoption by patients.

 

 

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by elevated blood pressure in and blockage of pulmonary arterioles, due to defective endothelial function and abnormal proliferation of the pulmonary artery smooth muscle cells and fibroblasts. Current therapies for pulmonary arterial hypertension do not provide a cure and their use can be limited due to systemic side effects. Consequently, there is a critical need to discover and develop new drugs that target vascular remodeling and provide long-term disease reversal benefits. Drug repurposing can bypass common challenges of drug discovery and offer shorter developmental cycles. This article describes the pathology of PAH and discusses a variety of drugs repurposed for inhalation that have undergone or are currently in clinical trials. Further research is warranted to establish these repurposed, inhaled drugs for use alone or in combination with existing therapies.

 

 

Information on upcoming industry events

Please visit the calendar on Inhalation's website for more conferences, which may change from live to virtual formats and have new dates due to COVID-19.

 

 

 

Questions about Inhalation, contact Vicki Schuman, Editor at vschuman@cscpub.com.

w: Inhalation Magazine • e: inhalationmag@cscpub.com

 

 

---

 

This email was sent to you from inhnews@cscpub2.com. To ensure delivery of these emails in your inbox,
please add us to your safe sender list. Privacy Policy • Unsubscribe

CSC Publishing • 1155 Northland Dr • St Paul, MN 55120